Sage Therapeutics, Inc. (SAGE) Position Boosted by TD Asset Management Inc.

TD Asset Management Inc. boosted its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 9.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 83,918 shares of the biopharmaceutical company’s stock after acquiring an additional 7,288 shares during the quarter. TD Asset Management Inc. owned 0.22% of Sage Therapeutics worth $5,228,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of SAGE. Bank of New York Mellon Corp lifted its holdings in shares of Sage Therapeutics by 36.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 2,710,027 shares of the biopharmaceutical company’s stock worth $168,834,000 after buying an additional 724,494 shares during the period. BlackRock Inc. lifted its holdings in shares of Sage Therapeutics by 5.9% in the 2nd quarter. BlackRock Inc. now owns 3,031,548 shares of the biopharmaceutical company’s stock worth $241,431,000 after buying an additional 168,424 shares during the period. New York State Common Retirement Fund lifted its holdings in shares of Sage Therapeutics by 258.0% in the 3rd quarter. New York State Common Retirement Fund now owns 149,564 shares of the biopharmaceutical company’s stock worth $9,318,000 after buying an additional 107,782 shares during the period. Farallon Capital Management LLC purchased a new stake in shares of Sage Therapeutics in the 2nd quarter worth $7,964,000. Finally, Pioneer Investment Management Inc. lifted its holdings in shares of Sage Therapeutics by 126.9% in the 2nd quarter. Pioneer Investment Management Inc. now owns 158,418 shares of the biopharmaceutical company’s stock worth $12,616,000 after buying an additional 88,585 shares during the period. Institutional investors own 95.40% of the company’s stock.

Shares of Sage Therapeutics, Inc. (SAGE) opened at $89.79 on Wednesday. Sage Therapeutics, Inc. has a 12 month low of $44.55 and a 12 month high of $100.50.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.98) by $0.01. Sage Therapeutics’s revenue was up .0% compared to the same quarter last year. equities research analysts predict that Sage Therapeutics, Inc. will post -7.4 EPS for the current year.

Several equities research analysts have weighed in on SAGE shares. Royal Bank Of Canada upped their target price on Sage Therapeutics from $117.00 to $120.00 in a report on Thursday, November 2nd. Goldman Sachs Group reiterated a “buy” rating and issued a $87.00 target price on shares of Sage Therapeutics in a report on Friday, October 6th. Needham & Company LLC lowered their target price on Sage Therapeutics from $95.00 to $86.00 and set a “buy” rating for the company in a report on Wednesday, September 13th. Stifel Nicolaus reiterated a “buy” rating and issued a $91.00 target price (down from $104.00) on shares of Sage Therapeutics in a report on Wednesday, September 13th. Finally, SunTrust Banks reiterated a “buy” rating and issued a $82.00 target price (down from $95.00) on shares of Sage Therapeutics in a report on Wednesday, September 13th. Three equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $105.14.

COPYRIGHT VIOLATION NOTICE: “Sage Therapeutics, Inc. (SAGE) Position Boosted by TD Asset Management Inc.” was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://sportsperspectives.com/2017/12/06/sage-therapeutics-inc-sage-position-boosted-by-td-asset-management-inc.html.

Sage Therapeutics Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Institutional Ownership by Quarter for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply